I-Mab Stock Discussion

$I-Mab (IMAB.US)$
ROCKVILLE, Md., Oct. 30, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced the presentation of a poster highlighting Phase 1 optimized dose estimation data for givastomig monotherapy (TJ033721/ABL111), a novel first-in-class Claudin18....

$I-Mab (IMAB.US)$ Mab Reports Poster Presentation Highlighting Top-line Results From Its Ongoing Phase 1 Clinical Study Of Givastomig AT ESMO 2024
Benzinga· 1 min ago
Expanded Phase 1 monotherapy study of givastomig, a Claudin 18.2 X 4-1BB bispecific antibody immunostimulant, shows promising single-agent activity in heavily pre-treated patients with gastric cancers expressing Claudin 18.2 at low and high levels.The recommended Phase 2 dose for givastomig was determined to be 8-12 mg/kg; giv...

$I-Mab (IMAB.US)$
I-Mab Presents Positive Uliledlimab Pharmacokinetics Data at 2024 World Conference on Lung Cancer
- Pharmacokinetic/pharmacodynamic (PK/PD) modeling data from three Phase 1 studies providing dosing support for upcoming clinical trials
- Exposure-Response (E-R) Analysis showed a positive correlation between uliledlimab concentration and ORR probability in mNSCLC patients
- Randomized Phase 2 study of uliledlimab in combination with pembrolizumab plus chemotherapy expected to ...

Gapping up
Select biotech/pharma names showing strength following ESMO:
$Clovis Oncology (CLVS.US)$ +11.3%, $Cardiff Oncology (CRDF.US)$ +9%, $Immatics (IMTX.US)$ +8.3%, $IDEAYA Biosciences (IDYA.US)$ +8%, $Lyra Therapeutics (LYRA.US)$ +5.7%, $POINT Biopharma (PNT.US)$ +5.7%, $Edgewise Therapeutics (EWTX.US)$ +4.7%, $Concert Pharmaceuticals (CNCE.US)$ +3.6%, $Deciphera Pharmaceuticals (DCPH.US)$ +3.2%, $Veracyte (VCYT.US)$ +2.6%, $SpringWorks Therapeutics (SWTX.US)$ +2.3%,...

this one is going on the watch list
$I-Mab (IMAB.US)$
this pharmaceutical company has tons of potential big money makers in the pipeline. if just one of these Cancer drugs gets approved then it will be a lot of money to be made for this very cheap ticker. they're also anticipating being listed in mainland China and in Hong Kong. this could be a bullish catalyst in the future even without any of the drugs being approv...

Gainers:
• $GTY Technology (GTYH.US)$ +118.1% (entered into a definitive agreement to be acquired by GI Partners )
• $Finch Therapeutics (FNCH.US)$ +68.33% (announces removal of FDA clinical hold on CP101 IND)
• $Zymeworks (ZYME.US)$ +42.34% (confirms receipt of non-binding proposal from All Blue Falcons for $10.50 per share in cash)
• $Hub Group (HUBG.US)$ +16.3% (earnings reports)
• $Lantheus (LNTH.US)$ +14.2% (earnings reports)
• $Mohawk Industries (MHK.US)$ +13.7% (e...

Gainers:
• $AlloVir (ALVR.US)$ +23.11% (announced that the U.S. Food and Drug Administration has granted Regenerative Medicine Advanced Therapy designation to its lead investigational multi-virus-specific T cell therapy posoleucel)
• $I-Mab (IMAB.US)$ +13% (report that the company is considering sale)
• $ASML Holding (ASML.US)$ +5.2% (earnings report)
• $Humanigen (HGEN.US)$ +4.4% (Announces Peer-Reviewed Publication Demonstrating the P...